Pain pills may cut risk of bowel cancer: study

By Joene Hendry

NEW YORK (Reuters Health) - Use of a non-steroidal anti-inflammatory drug (NSAID) for over 5 years may lessen a person’s risk of developing cancer of the lower portion of the large bowel, study findings suggest.

This risk reduction appears more robust among whites than among African Americans, Dr. Sangmi Kim, of the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina, and colleagues found.

The investigators evaluated use of NSAIDs (i.e., aspirin, ibuprofen, and selective COX-2 inhibitors, taken to ease pain and inflammation) among 1,057 white and African American men and women with cancer of the lower bowel and rectum and 1,019 individuals who were cancer-free.

The participants with cancer included 790 whites and 267 African Americans, of whom 76 percent reported ever using NSAIDs during the 5 years prior to diagnosis. Of the cancer-free group, 83 percent reported NSAID use during the 5 years prior to study participation.

Compared with those never using NSAIDs, NSAID use was associated with about 40 percent reduced risk for cancer in the lower portion of the large bowel overall, after allowing for age, gender, race, body mass, physical activity, and other factors potentially associated with distal large bowel cancers.

In analyses that factored for race, the investigators found a “strongly protective” association between NSAIDs and large bowel cancer in whites, according to a report in the American Journal of Epidemiology.

“However,” Kim told Reuters Health, “the risk reduction associated with NSAID use was less evident among African Americans.”

Risk reduction was slightly stronger with prescription, rather than non-prescription NSAID use, but again this association was stronger among whites than among African Americans.

The apparent protective effect between NSAID use and cancer of the lower portion of the large bowel noted in this study is similar to that previously reported between NSAIDs and colon cancer.

Nonetheless, Kim and colleagues say more study is needed before recommending NSAIDs for the prevention of colorectal cancer in the general public.

SOURCE: American Journal of Epidemiology, December 1, 2008


Related Posts:

NEW YORK (Reuters Health) - Cancer news stories and public service announcements that call attention to the fact that African Americans are often diagnosed with cancer at later stages and have lower survival rates than whites may discourage African Americans from getting screened for cancer, new research shows. “We have typically assumed that one of the

Full Post: Negative messages keep blacks from cancer tests

By Anne Harding NEW YORK (Reuters Health) - People with a type of cancer known as non-Hodgkin lymphoma, or NHL, are less likely to get appropriate treatment, and more likely to die of the disease, if they fall into a lower rather than higher socioeconomic level, a study in the journal Cancer shows. NHL mortality was higher

Full Post: Socioeconomics play into lymphoma survival

NEW YORK (Reuters Health) - Older African-American, Native American and non-white Hispanic women are more likely to develop arthritis than their white counterparts, and the larger prevalence of obesity among these ethnic groups may help explain why, new research shows. Among 146,494 women participating in the Women’s Health Initiative — an ongoing study of an ethnically

Full Post: Ethnic differences in arthritis due to obesity

By Anne Harding NEW YORK (Reuters Health) - Older African Americans more likely to rate their health as poor compared with older white Americans, even though when the two groups “are functioning extremely well, new research suggests. In a group of healthy Medicare-eligible patients in their 70s, African Americans consistently rated their health worse than did whites,

Full Post: Black seniors perceive health status differently

NEW YORK (Reuters Health) - The long-term use of hormone replacement therapy, which older women abandoned in droves following the news that it may increase the risk of breast cancer, may substantially cut the risk of colorectal cancer, research shows. The greatest risk reduction — 48 percent — was observed among women who had used a

Full Post: Hormone therapy may cut colorectal cancer risk

Site Navigation

Most Read